(Q52193324)

26 April 2018

title

Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. (English)

1 reference

26 April 2018

1 reference

1

1 reference

26 April 2018

author name string

Rodgers RJ

series ordinal

2

1 reference

26 April 2018

Perrault G

series ordinal

3

1 reference

26 April 2018

Sanger DJ

series ordinal

4

1 reference

26 April 2018

language of work or name

English

0 references

publication date

1 August 1997

1 reference

26 April 2018

Pharmacology, Biochemistry and Behavior

published in

1 reference

26 April 2018

volume

57

1 reference

26 April 2018

issue

4

1 reference

26 April 2018

page(s)

817-827

1 reference

26 April 2018

Diazepam changes risk assessment in an anxiety/defense test battery.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Evidence for differential effects of 8-OH-DPAT on male and female rats in the Anxiety/Defense Test Battery.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

The role of 5-HT1A serotonin and D2 dopamine receptors in buspirone effects on cortical electrical activity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Ethopharmacological analysis of rat behavior on the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Use of the elevated plus maze in the search for novel anxiolytic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Interactions between 5-hydroxytryptamine (5-HT) and testosterone in the control of sexual and nonsexual behaviour in male and female rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Benzodiazepines, putative anxiolytics and animal models of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

5-Hydroxytryptamine pathways in anxiety and its treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Buspirone: Effects on central monoaminergic transmission - possible relevance to animal experimental and clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Two tests in rats for antianxiety effect of clinically anxiety attenuating antidepressants.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

The ambivalent behaviour "stretched approach posture" in the rat as a paradigm to characterize anxiolytic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

A step in the right direction: comment on '5-HT and mechanisms of defence'

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Effects of ritanserin and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety: an ethopharmacological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Are 5-HT2 antagonists endowed with anxiolytic properties in rodents?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Dopamine and antianxiety activity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Anxiogenic stimuli in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900402-9

7 January 2021

10.1016/S0091-3057(96)00402-9

Identifiers

DOI

1 reference

26 April 2018

PubMed ID

9259011

1 reference

26 April 2018